Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

June 29, 2022

Trevi reports positive results in trial of Haduvio for skin condition

PHOTO | CONTRIBUTED Trevi Therapeutics CEO Jennifer Good
By Liese Klein

New Haven-based Trevi Therapeutics, Inc. reported positive results Wednesday in a trial of its drug Haduvio for treatment of prurigo nodularis, a chronic inflammatory skin disease.

The good news came from a Phase 2b/3 study of Haduvio for treatment of the disease, which has no approved therapies and manifests as an itch-scratch cycle that is difficult to stop and negatively impacts patients’ quality of life.

Trevi CEO Jennifer Good said, “This positive trial in prurigo nodularis, along with the highly statistically significant data from the interim analysis of our Phase 2 trial in [idiopathic pulmonary fibrosis] chronic cough that we presented earlier this year, further supports our belief that Haduvio could potentially benefit patients across a broad range of refractory chronic pruritic and cough conditions."

In March the company reported positive results in a trial of Haduvio as a treatment of chronic cough in idiopathic pulmonary fibrosis patients, ending the study early.

Haduvio works on opioid receptors in the central and peripheral nervous systems, a pathophysiology involved in both prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis.

In April, Trevi announced it had raised $55 million in a private-placement deal to help develop Haduvio.

Contact Liese Klein at lklein@newhavenbiz.com.
 

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF